Healthcare Private Placement and M&A Transactions Review Week Ending June 8, 2025

Antheia: The company raised $56 million of Series C venture funding in a deal led by EDBI and Global Health Investment Corporation on June 3, 2025. Echo Investment Capital, Sherpalo Ventures, Civilization Ventures, Federov, In-Q-Tel, S-Cubed Capital, Viking Global Investors, Athos (Family Office) and other undisclosed investors also participated in the round. The company is a developer of synthetic biology to produce biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines.

SpyGlass Pharma: The company raised $75 million of Series D venture funding in a deal led by Sands Capital on June 2, 2025, putting the company’s pre-money valuation at $280 million. New Enterprise Associates, Vensana Capital, RA Capital Management, Samsara BioCapital, Vertex Ventures HC, Gilde Healthcare, and other undisclosed investors also participated in the round. The company is a developer of pharmaceutical and healthcare products designed for the development and distribution of generic medicines and active pharmaceutical ingredients.

Allay Therapeutics: The company raised $57.5 million of Series D venture funding in a deal led by Lightstone Ventures and ClavystBio on June 5, 2025, putting the company’s pre-money valuation at $68.5 million. SGInnovate, EDBI, Brandon Capital, New Enterprise Associates, Arboretum Ventures, Vertex Ventures HC, Vertex Growth, Nea, Maruishi Pharmaceutical and IPD Capital also participated in the round. The company is a developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians.

Reprieve Cardiovascular: The company raised $40.4 million of venture funding from undisclosed investors on June 5, 2025. The company is a developer of an acute decompensated heart failure (ADHF) treatment medical device.

Beckley Psytech: The company raised $30 million of venture funding from Ferring Ventures and Adage Capital Management on June 2, 2025. The company is a developer of a clinical-stage biotechnology platform designed to transform psychedelics into effective medicines for neuropsychiatric disorders.

Matterworks: The company raised an estimated $23 million of Series A venture funding in a deal led by Lewis & Clark AgriFood and OMX Ventures on June 3, 2025, putting the company’s pre-money valuation at $39 million. Intermountain Ventures, Pillar VC, Germin8 Ventures, and Tarsadia Investments also participated in the round. The company is a developer of an artificial intelligence platform intended to drive the adoption of metabolomics across the life sciences.

ClearNote Health: The company raised $21.8 million of Series D venture funding from undisclosed investors on June 5, 2025. The company is a developer of a proprietary epigenomic technology designed to detect high-mortality cancers at an early, more treatable stage through a standard blood draw.

Akadeum Life Sciences: The company raised $20 million of venture funding in a deal led by Michigan Capital Network on June 3, 2025. NYBC Ventures, Arboretum Ventures and other undisclosed investors also participated in the round. The company is a developer of bio-separation products designed to facilitate the removal of target cells from biological samples.

Signify Bio: The company raised $15 million of venture funding in a deal led by Actium on June 6, 2025. Danaher, Eli Lilly, BrightEdge, and Gates Foundation also participated in the round. The company is an operator of a biotechnology platform designed to transform the development of in situ protein therapeutics.

OncoNano Medicine: The company raised $12.7 million of Series B venture funding from undisclosed investors on June 3, 2025, putting the company’s pre-money valuation at $47.3 million. The company is a developer of a nanotechnology platform designed to improve the delivery and activation of cancer therapies in acidic tumor environments.

PreciseDx: The company raised $11.2 million of venture funding from undisclosed investors on June 5, 2025. The company is a developer of artificial intelligence-guided pathology diagnostics designed to improve patient outcomes in the fields of cancer and other diseases.

BePharBel Manufacturing: The company raised EUR 8.9 million of venture funding from undisclosed investors on June 4, 2025, putting the company’s pre-money valuation at EUR 14.7 million. The company is a manufacturer of pharmaceutical and para-pharmaceutical products intended to provide efficient and reliable medicines at accessible prices.

Immunomic Therapeutics: The company raised $6.5 million of venture funding from undisclosed investors on June 2, 2025. The company is a developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health.

Accelus: The company raised $6 million of venture funding in a deal led by Concord Health Partners on June 6, 2025. The company is a developer of medical implants designed to focus on expandable interbody technology for spine surgery.

Kamau Therapeutics: The company raised $5 million of venture funding from undisclosed investors on June 3, 2025. The company is an operator of a clinical-stage, next-generation gene correction company intended to cure serious and life-threatening diseases.

Gleamer: The company raised venture funding from undisclosed investors on June 5, 2025. The company is a developer of a radiology technology designed to detect and highlight bone abnormalities.

Otomo Health: The company raised an undisclosed amount of venture funding from Milemark Capital in approximately May 2025. The company is a developer of real-time voice AI and machine learning algorithms to improve revenue cycle management efficiency and automate administrative tasks, initially focusing on gastrointestinal endoscopies.

Wandercraft: The company raised an undisclosed amount of venture funding from Renault on June 6, 2025. The company is a developer of a self-balancing robotic exoskeleton designed to enable paralysed users to stand up and walk again, hands-free, without crutches.

Perch / Catapult Group International: The company was acquired by Catapult Group International for $18 million on June 5, 2025. The company is a developer of a velocity-based training equipment designed to quantify complex and functional movement exercises.

Blueprint Medicines / Sanofi: The company reached a definitive agreement to be acquired by Sanofi for $9.5 billion on June 2, 2025. Blueprint Medicines Corp is a biopharmaceutical company engaged in developing medicines in the areas of allergy, inflammation, oncology, and hematology.

Beckley Psytech / ATAI Life Sciences: The company reached a definitive agreement to be acquired by ATAI Life Sciences for $370 million on June 2, 2025. The company is a developer of a clinical-stage biotechnology platform designed to transform psychedelics into effective medicines for neuropsychiatric disorders.

Biocrates / Bruker: The company was acquired by Bruker for an undisclosed amount on June 3, 2025. The company is a developer of a metabolomics platform that uses a mass-spectrometry-based technology platform to identify, quantify, and map metabolites.

Cellular Highways / StemCell Technologies: The company was acquired by StemCell Technologies for an undisclosed amount on June 3, 2025. The company is a developer of an automated high-throughput cell sorting instrument designed to simplify and enhance the efficiency of cell sorting processes.

doctorly / FREY: The company was acquired by FREY (Enterprise Systems) for an undisclosed amount on June 5, 2025. The company is a developer of a cloud-based practice management platform for doctors.

EBI / Avista Healthcare Partners: The company, a subsidiary of Highridge Medical, was acquired by Avista Healthcare Partners through an LBO on June 4, 2025 for an undisclosed amount. The company is a manufacturer of a medical device designed to enhance bone regeneration and accelerate healing in patients.

Embold Health / Quantum Health: The company entered into a definitive agreement to be acquired by Quantum Health, via its financial sponsors Great Hill Partners and Warburg Pincus, through an LBO on June 4, 2025 for an undisclosed amount. The company is a an operator of a doctor-led health care analytics company that helps employers identify and guide their members to high-performing doctors.

Fifth Eye / AirStrip: The company was acquired by AirStrip for an undisclosed amount on June 3, 2025. The company is a developer of clinical decision support software designed to predict a patient’s risk of hemodynamic instability.

Focal Medical / Continuity Biosciences: The company was acquired by Continuity Biosciences for an undisclosed amount on June 4, 2025. The company is a developer of novel drug delivery systems created for cancers that are difficult to treat with systemic therapy alone.

Limber Health / Net Health Systems: The company was acquired by Net Health Systems, via its financial sponsors ACE & Company, Level Equity, and The Carlyle Group, through an LBO on June 3, 2025 for an undisclosed amount. The company is an operator of a hybrid model for in-person and digital musculoskeletal care.

Ro5 / Juvenescence: The company reached a definitive agreement to be acquired by Juvenescence for an undisclosed amount on June 5, 2025. The company is a developer of a drug discovery platform intended to accelerate research and development in the biopharma industry.

Veda / H1 Insights: The company was acquired by H1 Insights for an undisclosed amount on June 3, 2025. The company is a developer an automated data management platform designed to improve healthcare provider directories.